93 related articles for article (PubMed ID: 14534746)
21. Best immunohistochemical panel in distinguishing adenocarcinoma from squamous cell carcinoma of lung: tissue microarray assay in resected lung cancer specimens.
Kim MJ; Shin HC; Shin KC; Ro JY
Ann Diagn Pathol; 2013 Feb; 17(1):85-90. PubMed ID: 23040737
[TBL] [Abstract][Full Text] [Related]
22. Medullary thyroid carcinoma: prognostic factors.
Riddell DA; Lampe HB; Cramer H; Troster M
J Otolaryngol; 1993 Jun; 22(3):180-3. PubMed ID: 7690409
[TBL] [Abstract][Full Text] [Related]
23. Anaplastic thyroid carcinoma. A study of 70 cases.
Carcangiu ML; Steeper T; Zampi G; Rosai J
Am J Clin Pathol; 1985 Feb; 83(2):135-58. PubMed ID: 2578727
[TBL] [Abstract][Full Text] [Related]
24. An immunohistochemical study of cytokeratin and vimentin in benign and malignant thyroid lesions.
Uchida H; Nakayama I; Noguchi S
Acta Pathol Jpn; 1989 Mar; 39(3):169-75. PubMed ID: 2472733
[TBL] [Abstract][Full Text] [Related]
25. Expression of intermediate filament proteins in subtypes of renal cell carcinomas and in renal oncocytomas. Distinction of two classes of renal cell tumors.
Pitz S; Moll R; Störkel S; Thoenes W
Lab Invest; 1987 Jun; 56(6):642-53. PubMed ID: 2439772
[TBL] [Abstract][Full Text] [Related]
26. Histological and functional correlation of thyroid carcinoma by immunohistochemistry.
Prathiba D; Rao KR; Madhavan M
Indian J Pathol Microbiol; 1990 Jan; 33(1):35-40. PubMed ID: 2394474
[TBL] [Abstract][Full Text] [Related]
27. Immunohistochemical detection of thyroid transcription factor-1, thyroglobulin, and calcitonin in canine normal, hyperplastic, and neoplastic thyroid gland.
Ramos-Vara JA; Miller MA; Johnson GC; Pace LW
Vet Pathol; 2002 Jul; 39(4):480-7. PubMed ID: 12126151
[TBL] [Abstract][Full Text] [Related]
28. Improvement of the cytological diagnostic accuracy of follicular thyroid lesions by the use of the Ki-67 proliferative index in addition to cytokeratin-19 and HBME-1 immunomarkers: a study of 61 cases of liquid-based FNA cytology with histological controls.
Lacoste-Collin L; d'Aure D; Bérard E; Rouquette I; Delisle MB; Courtade-Saïdi M
Cytopathology; 2014 Jun; 25(3):160-9. PubMed ID: 24460983
[TBL] [Abstract][Full Text] [Related]
29. Histologic variants of papillary and follicular carcinomas associated with anaplastic spindle and giant cell carcinomas of the thyroid: an analysis of rhabdoid and thyroglobulin inclusions.
Albores-Saavedra J; Hernandez M; Sanchez-Sosa S; Simpson K; Angeles A; Henson DE
Am J Surg Pathol; 2007 May; 31(5):729-36. PubMed ID: 17460457
[TBL] [Abstract][Full Text] [Related]
30. Frequency of medullary thyroid carcinoma in an endemic goiter area.
Schmid KW; Tötsch M; Hittmair A; Feichtinger H; Ladurner D; Hofstädter F
Mod Pathol; 1989 Mar; 2(2):90-3. PubMed ID: 2542931
[TBL] [Abstract][Full Text] [Related]
31. Poorly Differentiated and Undifferentiated Thyroid Carcinomas.
Eloy C; Ferreira L; Salgado C; Soares P; Sobrinho-Simões M
Turk Patoloji Derg; 2015; 31 Suppl 1():48-59. PubMed ID: 26177317
[TBL] [Abstract][Full Text] [Related]
32. Immunoexpression of HBME-1, high molecular weight cytokeratin, cytokeratin 19, thyroid transcription factor-1, and E-cadherin in thyroid carcinomas.
Choi YL; Kim MK; Suh JW; Han J; Kim JH; Yang JH; Nam SJ
J Korean Med Sci; 2005 Oct; 20(5):853-9. PubMed ID: 16224162
[TBL] [Abstract][Full Text] [Related]
33. Medullary differentiation of anaplastic thyroid carcinoma.
Nieuwenhuijzen Kruseman AC; Bosman FT; van Bergen Henegouw JC; Cramer-Knijnenburg G; Brutel de la Riviere G
Am J Clin Pathol; 1982 May; 77(5):541-7. PubMed ID: 6177234
[TBL] [Abstract][Full Text] [Related]
34. Molecular diversity of cytokeratins: significance for cell and tumor differentiation.
Moll R
Acta Histochem Suppl; 1991; 41():117-27. PubMed ID: 1725827
[TBL] [Abstract][Full Text] [Related]
35. Targeted therapy: a new hope for thyroid carcinomas.
Perri F; Pezzullo L; Chiofalo MG; Lastoria S; Di Gennaro F; Scarpati GD; Caponigro F
Crit Rev Oncol Hematol; 2015 Apr; 94(1):55-63. PubMed ID: 25465739
[TBL] [Abstract][Full Text] [Related]
36. CD56 expression in benign and malignant thyroid lesions.
Muthusamy S; Azhar Sha S; Abdullah Suhaimi SN; Kassim N; Mahasin M; Mohd Saleh MF; Md Isa N
Malays J Pathol; 2018 Aug; 40(2):111-119. PubMed ID: 30173227
[TBL] [Abstract][Full Text] [Related]
37. Novel BRAF and KRAS Mutations in Papillary Thyroid Carcinoma Arising in Struma Ovarii.
Tan A; Stewart CJ; Garrett KL; Rye M; Cohen PA
Endocr Pathol; 2015 Dec; 26(4):296-301. PubMed ID: 26362194
[TBL] [Abstract][Full Text] [Related]
38. Simultaneous immunohistochemical expression of HBME-1 and galectin-3 differentiates papillary carcinomas from hyperfunctioning lesions of the thyroid.
Rossi ED; Raffaelli M; Mule' A; Miraglia A; Lombardi CP; Vecchio FM; Fadda G
Histopathology; 2006 Jun; 48(7):795-800. PubMed ID: 16722927
[TBL] [Abstract][Full Text] [Related]
39. Usefulness of HBME-1, cytokeratin 19 and galectin-3 immunostaining in the diagnosis of thyroid malignancy.
de Matos PS; Ferreira AP; de Oliveira Facuri F; Assumpção LV; Metze K; Ward LS
Histopathology; 2005 Oct; 47(4):391-401. PubMed ID: 16178894
[TBL] [Abstract][Full Text] [Related]
40. Necrosis in 84 ovarian carcinomas: a morphologic study of primary versus metastatic colonic carcinoma with a selective immunohistochemical analysis of cytokeratin subtypes and carcinoembryonic antigen.
DeCostanzo DC; Elias JM; Chumas JC
Int J Gynecol Pathol; 1997 Jul; 16(3):245-9. PubMed ID: 9421090
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
